Antimicrobial de-escalation in the critically ill patient and assessment of clinical cure: the DIANA study

Liesbet de Bus , Pieter Depuydt , Johan Steen , Sofie Dhaese , Ken de Smet , Alexis Tabah (1) , Murat Akova , Menino Osbert Cotta , Gennaro de Pascale , George Dimopoulos (2) , Shigeki Fujitani , Jose Garnacho-Montero , Marc Leone (3, 4) , Jeffrey Lipman (5) , Marlies Ostermann , José-Artur Paiva (6) , Jeroen Schouten (7) , Fredrik Sjövall (8) , Jean-François Timsit (9) , Jason Roberts , Jean-Ralph Zahar (10) , Farid Zand , Kapil Zirpe , Jan de Waele (11)

1 Clinique de réanimation médicale
2 Johns Hopkins Bloomberg School of Public Health [Baltimore]
3 MEPHI - Microbes évolution phylogénie et infections
4 Service Anesthésie et Réanimation [Hôpital Nord - APHM]
5 UQ [All campuses : Brisbane, Dutton Park Gatton, Herston, St Lucia and other locations] - The University of Queensland
6 Universidade do Porto = University of Porto
7 Radboud University Medical Center [Nijmegen]
8 Skane University Hospital [Malmo]
9 INSERM U823 - Institut d'oncologie/développement Albert Bonniot de Grenoble
10 Hôpital Avicenne [AP-HP]
11 Ghent University Hospital, Ghent, Belgium

The DIANA study aimed to evaluate how often antimicrobial de-escalation (ADE) of empirical treatment is performed in the intensive care unit (ICU) and to estimate the effect of ADE on clinical cure on day 7 following treatment initiation.

Domaines: Bactériologie; Cardiologie et système cardiovasculaire; Maladies émergentes; Maladies infectieuses; Parasitologie; Virologie

Liesbet de Bus, Pieter Depuydt, Johan Steen, Sofie Dhaese, Ken de Smet, et al.. Antimicrobial de-escalation in the critically ill patient and assessment of clinical cure: the DIANA study. Intensive Care Medicine, 2020, ⟨10.1007/s00134-020-06111-5⟩. ⟨hal-02869005⟩